My first experience with Clive Bennett, Halo Pharma’s chief executive officer, was this past January when I was looking for a comment about the proposed Generic Drug User Fee Act. He e-mailed a well-thought-out takedown of the Act’s imposition of inspection fees on CMOs, and ended with “And you can quote me on that.” I thought, “Now that is someone I need to interview!” We sat down at his office in Whippany, NJ in April, shortly after the announcement that Halo had acquired Teva’s (formerly Ratiopharm’s) Mirabel manufacturing facility, near Montreal. When that deal closes, Halo will nearly double in both sales and staff. Mr. Bennett talked with me about his lessons learned over his 40-year pharma career, with the same unique combination of bluntness and deep consideration he showed in our GDUFA conversation. —GYR
Contract PhaContinue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
